Distinct patterns of somatic mutation clearance and association
28-day oral (gavage) toxicity studies of green tea catechins prepared for beverages in rats
141 An RCT 157 evaluated the effect of 26 weeks of once-weekly exenatide treatment on the frequency of heavy drinking days in patients diagnosed with AUD
Market Players, Key Developments, and Competitive Intelligence To learn more about this report, Key Developments On June 30, 2025, Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on peptide-based therapeutics, announced the nomination of PN-477, a triple agonist peptide targeting GLP-1, GIP, and GCG receptors, for obesity treatment
Caffeine-free suitable for everyday use
Making the Most of Your Vitamin C Routine Split doses throughout the day especially for higher amounts of regular, non-liposomal vitamin C